Wall Street analysts expect Puma Biotechnology Inc (NYSE:PBYI) to announce earnings of ($2.36) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Puma Biotechnology’s earnings. The highest EPS estimate is ($1.27) and the lowest is ($4.28). Puma Biotechnology posted earnings of ($1.11) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 112.6%. The business is expected to announce its next earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Puma Biotechnology will report full year earnings of ($8.78) per share for the current fiscal year, with EPS estimates ranging from ($10.54) to ($7.75). For the next fiscal year, analysts expect that the firm will post earnings of ($4.30) per share, with EPS estimates ranging from ($9.01) to $1.06. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Puma Biotechnology.

Puma Biotechnology (NYSE:PBYI) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the consensus estimate of ($1.32) by $0.78.

A number of equities research analysts recently commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $105.00 price target on shares of Puma Biotechnology in a research report on Monday, June 5th. Leerink Swann restated an “outperform” rating and issued a $125.00 price objective on shares of Puma Biotechnology in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Credit Suisse Group upped their price objective on Puma Biotechnology from $58.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 25th. Finally, Citigroup Inc. restated a “buy” rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $108.90.

In other news, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the completion of the transaction, the insider now owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Richard Paul Bryce sold 1,998 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the transaction, the senior vice president now owns 27,246 shares of the company’s stock, valued at approximately $2,574,202.08. The disclosure for this sale can be found here. Insiders have sold a total of 267,433 shares of company stock valued at $21,732,262 in the last quarter. 22.70% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its stake in shares of Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 140 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Puma Biotechnology by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock worth $1,950,000 after acquiring an additional 437 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Puma Biotechnology during the 2nd quarter worth $146,000. Janus Henderson Group PLC bought a new position in shares of Puma Biotechnology during the 2nd quarter worth $162,302,000. Finally, Kazazian Asset Management LLC bought a new position in shares of Puma Biotechnology during the 2nd quarter worth $209,000. Institutional investors own 80.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/08/brokerages-anticipate-puma-biotechnology-inc-pbyi-to-announce-2-36-eps.html.

Puma Biotechnology (PBYI) opened at 107.40 on Friday. The company’s market capitalization is $4.00 billion. The company has a 50 day moving average of $88.12 and a 200 day moving average of $63.32. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $107.65.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.